Molecules, Volume 21, Issue 4
2016 April - 149 articles
Cover Story: With its epidemic proportion and an attrition rate approaching 100%, Alzheimer’s disease (AD) is an extremely frustrating drug discovery field. Unlike many other major diseases, no medicine has been found to cure or even slow the course of AD. Recently, a small ray of hope has broken through the gloomy outcomes associated with AD: the development of the so-called multitarget drugs. These are single molecules which, acting simultaneously on different pharmacological targets of the disease network, are inherently more adequate to confront AD complex brain pathology. In this issue, Maria Laura Bolognesi, University of Bologna, Italy, and colleagues argue in support of a multitarget drug discovery strategy as a powerful way to develop new, effective, anti-AD drugs. At the same time, they also warn that challenges remain and there is much to learn as we embark on this journey to move them from bench to bedside. View the paper - Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
- You may sign up for email alerts to receive table of contents of newly released issues.
- PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.
